Industry News

• Emergent BioSolutions Chairman and CEO Fuad El-Hibri recognized  Emergent BioSolutions announced that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland's outstanding international business leaders.
  Emergent Biosolutions Inc. March 11, 2010  
• Hanger patient Staff Sgt. Heath Calhoun competing in 2010 Paralympic Winter Games  As Hanger patient Staff Sgt. Heath Calhoun gets set to compete in the 2010 Paralympic Winter Games as an alpine skier, his story will be featured on NBC Nightly News.
  Hanger Orthopedic Group March 11, 2010  
• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• NPS Pharmaceuticals reports 2009 results and 2010 outlook  NPS reported a net loss of $2.0 million or $0.04 per diluted share for the fourth quarter of 2009, compared to a net loss of $8.5 million or $0.18 per diluted share for the fourth quarter of 2008.
  NPS Pharmaceuticals, Inc. March 11, 2010  
• GenVec reports fourth quarter and 2009 year-end financial results  For the year ended December 31, 2009, the Company reported a net loss of $18.4 million, or $0.19 per share, compared with a net loss of $26.1 million, or $0.31 per share for the year ended December 31, 2008.
  GenVec, Inc. March 11, 2010  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott March 11, 2010  
• Cordis unveils next generation CoCr coronary stent  Cordis Corporation announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances.
  Johnson & Johnson March 11, 2010  
• Hi-Tech Pharmacal reports results for the third fiscal quarter ended January 31, 2010  For the three months ended January 31, 2010, the Company reported net sales of $38.8 million, an increase of 32% from $29.4 million for the same period last year.
  Hi-Tech Pharmacal Co., Inc. March 11, 2010  
• Orchid Cellmark reports fourth quarter and year-end 2009 financial results  Total revenues were $15.7 million for fourth quarter 2009, an increase of 21%, compared to $13.0 million for the fourth quarter of 2008. For full year 2009, revenues were $59.1 million, an increase of 3%, compared to $57.6 million for the full year of 2008.
  Orchid Cellmark Inc. March 11, 2010  

   (next 10 articles)